Navigating AI-Driven Pharmaceutical Visual Inspection

The pharmaceutical industry continues to grapple with quality control issues. Traditional inspection methods are failing to meet the demands of modern production, with high-profile contamination incidents like stainless steel particles in Moderna vaccines exposing critical vulnerabilities.1 Manual inspection remains prone to human error, whilst conventional automated systems can only detect what they've been programmed to find. As regulatory scrutiny intensifies and production complexity increases, manufacturers need a solution. AI automated technology represents a sophisticated evolution in visual inspection that addresses fundamental limitations of both manual and traditional automated approaches. Promising to transform pharmaceutical quality assurance, artificial intelligence-driven inspection offers the capability to achieve zero-defect production whilst maintaining commercial viability.

The Regulatory Imperative

Regulatory bodies, including the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Medicines and Healthcare products Regulatory Agency (MHRA), are progressively expecting manufacturers to demonstrate robust quality control capabilities that extend beyond traditional compliance measures.

Current Good Manufacturing Practice (cGMP) incorporates strict contamination control protocols designed to prevent foreign particles from compromising pharmaceutical products, with enforcement becoming increasingly stringent across global markets.

The FDA's Guidance for Industry on the Inspection of Injectable Products for Visible Particulates requires that all medicinal products intended for parenteral administration be visually inspected for particulate matter, and that any container showing visible particulates must be rejected.2 In addition, the United States Pharmacopoeia guidance on visible particulates in injections establishes regulatory requirements for visual inspection of parenteral products, enforcing demonstration through 100% visual inspection that batches are 'essentially free of visible particulates,' before release.[3] These regulations underscore the critical importance of comprehensive inspection capabilities in pharmaceutical manufacturing.

Currently, no AI-specific regulations are in place, though the EU has drafted GMP Annex 22 (Artificial Intelligence) and Annex 11 (Computerised systems), which are under review. A key regulatory principle emerging from these drafts is that for critical GMP applications, only static or deterministic models are permitted, whilst dynamic or continually learning models are not acceptable for critical GMP uses.[4,5]

This regulatory framework means AI models must be locked and static when deployed in inspection machines for production, with self-learning capabilities reserved for development and future releases rather than automatic onsite production model updates.

Given that AI-specific regulations remain in draft stages, AI-based inspection machines are currently governed by the same regulatory framework as traditional inspection machines. The EU policy on automated visual inspection (AVI) states: 'where automated methods of inspection are used, the process should be validated to detect known defects (which may impact product quality or safety) and be equal to, or better than, manual inspection methods.'[6]

Many AI automated inspection systems support the various compliance frameworks by creating comprehensive audit trails that satisfy regulatory documentation requirements, providing manufacturers with defensible quality assurance processes.

Technological Advancement and Capabilities

AI automated technology represents a sophisticated evolution in visual inspection that addresses fundamental limitations of both manual and traditional automated approaches. Manual inspection remains subject to human error, fatigue, and inconsistency, whilst traditional automated inspection can only identify defects for which it has been explicitly programmed.[7] AI automated technology offers significant advantages, including novel defect detection capabilities and continuously improving detection through self-learning algorithms, fundamentally changing the inspection paradigm.

AI-based inspection machines achieve substantially reduced false negative rates, decreasing the percentage of acceptable products incorrectly rejected from 10-20% to approximately 2%.[8] This dramatic improvement in accuracy translates directly to significant cost savings and reduced waste. Additionally, AI technology can analyse sequences of images as video content, gaining insights from motion patterns and multi-angle views of suspected defects to inform final good or bad determinations, providing a more comprehensive assessment than static image analysis.

The operational mechanism of AI automated inspection involves training deep neural network models with extensive datasets comprising images of acceptable products, which are labelled good, alongside images of defective products, labelled bad, with defect areas indicated.

Comprehensive training typically utilises one million acceptable images and 2.5 million defective images. Acceptable images include perfectly good products as well as images containing expected distractions such as bubbles, scale marks, and engraved logos.

Defective images encompass typical contamination types within pharmaceutical products, including glass, particles, and metal contaminants, though the range of defect types need not be exhaustive. Following training, models learn to recognise features of acceptable products with expected distractions, contrasted against defective products.

During deployment, inspection machines capture multiple images of each product, feeding these to the model for good or bad determinations. Models render 'good,' judgments when all features contained in images match those expected from acceptable products. While 'bad' judgements are made when

either of two criteria are met: certain features align with defect patterns from training, or certain features do not conform to the acceptable product feature profile, even when not directly matched to a specific defect type.

This second criterion operates on a 'fail safe' principle, ensuring potentially problematic products are flagged for further evaluation. Inspection machines also assess capping defects, container cosmetic defects, and fill level control, each utilising separately trained deep neural network models following essentially identical methodologies.

Economic Benefits and Performance Metrics

AI automated inspection has the potential to deliver substantial cost-saving benefits through reduced labour costs, minimised waste, and avoidance of recall expenses. Implementing more sophisticated visual inspection technology can reduce regulatory compliance costs, prevent reputational damage from quality issues, and avoid loss of market opportunities. The most significant cost saving derives from waste reduction, with false rejection rates decreasing from approximately 15% to 2%, saving 13% of final products that would otherwise be unnecessarily discarded.[9]

Performance evaluation of inspection systems relies on two primary metrics: false negative rates (miss rates) and false positive rates (false rejections). False negative rates measure the percentage of defective products not rejected by the inspection process, whilst false positive rates measure the percentage of acceptable products mistakenly rejected. Probability of Detection (PoD) or detection rate represents the inverse of false negative rates, calculated as (1 - false negative percentage).

According to the United States Pharmacopeia, visual inspection is a probabilistic process rather than an absolute one, with detection likelihood influenced by particle size, shape, colour, density, and reflectivity. The human eye has a theoretical resolution limit of ~11 µm, though practical resolving power is closer to 85–100 µm. Under controlled conditions, manual inspection demonstrates a PoD only slightly above 0% for 50 µm particles, rising to about 40% for 100 µm single-seeded spherical particles (polystyrene beads), approximately 70% for 150 µm particles, and exceeding 90% for 200 µm and larger particles.[10]

For glass-based containers, where delamination or breakage makes glass particles a major contamination risk, differences in detection performance between methods are pronounced. Studies show that manual inspection detects only about 40% of units containing a single glass particle sized between 50–400 µm, missing the majority. By comparison, traditional automated inspection systems typically detect around 90%, while AI-based vision systems can achieve up to 98.5% detection, corresponding to a missed fraction of only 1.5%.[11] These performance improvements represent a substantial enhancement in safety and quality assurance for sterile products.

For plastic-based containers, where foreign matter is harder to distinguish due to transparency and refractive similarity, performance disparities are even more pronounced. Manual inspection achieves about 25% PoD for a single plastic particle, increasing to ~45% when five 400 µm particles are present. Traditional automated systems show limited capability, achieving ~65% detection, whereas AI-based inspection systems report ~95% PoD. Regarding false rejection rates, conventional machine vision is often confounded by bubbles and cosmetic features, resulting in 10–20% false rejections, compared with ~2% for AI-based systems, a performance level comparable to human inspection.[11]

Implementation Challenges and Solutions

Transitioning from manual or automated visual inspection to AI automated inspection presents specific challenges that manufacturers must navigate carefully. One

significant challenge involves setting explicit parameters for acceptance thresholds, which differs markedly from manual inspection, where acceptance thresholds are often verbally communicated and relatively vague. Pharmaceutical companies frequently encounter varied opinions on machine threshold settings among different departments, including quality control, production, and financial teams. Achieving consensus on numerical threshold levels can prove challenging during initial implementation phases, requiring careful change management and stakeholder alignment.

Successful implementation requires comprehensive validation processes that demonstrate equivalence or superiority to existing methods. Companies must establish robust training protocols for personnel operating new systems, develop standard operating procedures that accommodate AI-driven processes, and ensure integration with existing quality management systems. Additionally, manufacturers must address data governance requirements, including proper dataset curation, bias management, and comprehensive documentation of model development and validation processes.

Future Technological Developments

Visual inspection technologies continue evolving towards improved performance and broader applicability. Current development focuses on creating more generic computer vision neural network models, similar to trends in large language models. Present approaches require training different models for different container formats and, in some cases, different drug solutions. Given similarities between acceptable and defective samples and recent algorithmic developments, efforts are underway to combine and fuse different models into unified general inspection models. This consolidation saves customers effort in switching between models and reduces potential operational risks, whilst significantly alleviating machine manufacturers from numerous calibration iterations.

Depth of field limitations in camera imaging have constrained inspection capabilities for decades, particularly when detecting small particles within relatively large containers such as 30ml vials. Leveraging AI model predictive capabilities, algorithms are being developed to forecast particle trajectories in three-dimensional space based on the first 20% of image sequences. These predictions enable real-time liquid lens control to adjust camera focus planes according to predicted particle trajectories. This approach overcomes shallow depth of field limitations and obtains significantly sharper images of suspected particles. In doing so, false negative rates could be cut from 2% to 0.2%, and probability detection rates improved from 99% to 99.8%.[12]

Advanced AI techniques also enable enhanced defect classification and characterisation, providing manufacturers with more detailed information about contamination sources and patterns. Machine learning algorithms can identify trends in defect occurrence, supporting predictive maintenance programmes and process optimisation initiatives. These capabilities extend AI benefits beyond immediate inspection to broader manufacturing intelligence applications.

Strategic Implementation Considerations

Successful transition to AI-driven pharmaceutical visual inspection requires strategic planning that encompasses technical, regulatory, and organisational dimensions. Manufacturers must assess their current quality control infrastructure, identify specific improvement opportunities, and develop phased implementation approaches that minimise operational disruption. Regulatory considerations should inform technology selection and validation strategies, ensuring compliance with evolving requirements whilst positioning organisations for future regulatory developments.

Training and change management programmes are essential for successful implementation, as staff must understand new technologies and adapt established working practices. Quality assurance professionals require training in AI system validation and ongoing monitoring, whilst production personnel need familiarity with automated system operations and exception handling procedures. Management support and clear communication about implementation benefits help ensure organisational buy-in and successful technology adoption.

When it comes to financial considerations, decision-makers should evaluate not only initial capital costs but also ongoing operational benefits, including reduced waste, improved compliance, and enhanced product quality. Total cost of ownership analyses should incorporate labour savings, reduced recall risks, and competitive advantages from superior quality control capabilities.

Conclusion

The pharmaceutical industry stands at a defining moment. The leap from manual inspection to AI systems achieves much higher accuracy, representing more than a technological advancement as it embodies a turning point in how we safeguard human health. Manufacturers embracing this transformation are not merely upgrading equipment; they are positioning themselves as leaders in an industry where precision directly translates to lives protected and trust earned.

Whilst manual and traditional methods have likely reached their performance ceiling, AI-driven inspection continues evolving with algorithmic breakthroughs. Future developments could promise detection rates approaching 99.8%, transforming today's ambitious goals into tomorrow's minimum standards. The technology transcends business metrics, becoming an instrument of global health protection where every contaminated vial prevented represents a patient safeguarded.

As regulatory frameworks become increasingly stringent and market dynamics continue evolving, AI-driven visual inspection transitions from emerging technology to essential infrastructure. Forward-thinking manufacturers implementing

these systems today establish competitive advantages that will prove increasingly difficult to replicate. In a regulatory environment where quality assurance capabilities determine market access and operational sustainability, AI-driven inspection represents a fundamental component of future pharmaceutical manufacturing excellence.

REFERENCES

1. Chooi, W.H. *et al.* (2022) Vaccine contamination: Causes and control, Vaccine. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC8860342/ (Accessed: 20 August 2025).
2. (2021) Inspection of Injectable Products for Visible Particulates – Guidance for Industry. Available at: https://www.fda.gov/media/154868/download (Accessed: 20 August 2025).
3. (2014) The United States Pharmacopeia. Chapter 790. Available at: https://doi.usp.org/USPNF/USPNF_M7197_01_01.html (Accessed: 21 August 2025).
4. (2025) Annex 22: Artificial Intelligence. Available at: https://health.ec.europa.eu/document/download/5f38a92d-bb8e-4264-8898-ea076e926db6_en?filename=mp_vol4_chap4_annex22_consultation_guideline_en.pdf (Accessed: 20 August 2025).
5. (2011) Annex 11: Computerised Systems. Available at: https://health.ec.europa.eu/system/files/2016-11/annex11_01-2011_en_0.pdf (Accessed: 20 August 2025).
6. (2022) Annex 1: Manufacture of Sterile Medicinal Products. Available e05af55b-38e9-42bf-8495-194bbf0b9262_en (Accessed: 21 August 2025)
7. (2020) Vision Inspection Using Machine Learning/Artificial Intelligence. Pharmaceutical Engineering (November–December 2020). Available at: https://ispe.org/pharmaceutical-engineering/november-december-2020/vision-inspection-using-machine (Accessed: 20 August 2025).
8. Xin Weisheng (2025) Internal research on AI-driven visual inspection performance compared to traditional visual inspection machines. Unpublished internal data.
9. Xin Weisheng (2025) Internal research on AI-driven visual inspection performance compared to traditional visual inspection machines. Unpublished internal data.
10. Cherris, R. (2016) Visual Inspections of Injections – NGVF Masterclass Slides. PDA/PharmOut. Available at: https://www.pharmout.net/wp-content/uploads/2018/02/NGVF-2016-Visual-Inspections-of-Injection.pdf (Accessed: 21 August 2025).
11. Mazaheri, M. *et al.* (2024) 'Monitoring of Visible Particles in Parenteral Products by Manual Visual Inspection - Reassessing Size Threshold and Other Particle Characteristics that Define Particle Visibility', Journal of Pharmaceutical Sciences. Available at: https://www.sciencedirect.com/science/article/abs/pii/S0022354923004112 (Accessed: 28 August 2025)
12. Xin Weisheng (2025) Company prediction on future AI visual inspection detection rates. Unpublished internal estimate.

Yuting Shao

Yuting Shao, Director of Xin Weisheng, is a passionate serial entrepreneur with over 11 years of experience delivering customised solutions to international pharmaceutical clients. She is the Director of Xin Weisheng, a global leader in pharmaceutical machinery, specialising in aseptic processing lines, AI-driven visual inspection systems, and high-speed packaging solutions. Yuting holds a BA (Hons) in Economics from the University of Cambridge and an MBA from Judge Business School, University of Cambridge.